Resistance to Beta Lactam Antibiotics of Pseudomonas aeruginosa Isolated in Community Infections within HIV Infected Persons in Lomé-Togo


Objective: Describe resistance to beta lactam antibiotics of Pseudomonas aeruginosa in community infection within HIV-1 infected persons. Methods: We have studied prospectively from June 15th to December 31st 2013 inthe Clinic Hotel-Dieu and NGO VISA of Lomé, adult HIV-1 infected patients under anti retroviral therapy combining tenofovir, lamivudine and efavirenz for at least one year. The technique of agar diffusion susceptibility using discs of Ticarcillin + clavulanic acid is used to study the β-lactamase production. The diagnosis of species was performed by the chloroform test and the test for sensitivity to kanamycin and colistin. Results: Thirty five strains of Pseudomonas aeruginosa were obtained. The T-lymphocytes CD4 mediane was 575 cells/mm3 of blood. Urine represented 15 cases, skin abscesses 11 cases, externa suppurate otitis 7 cases and vaginal swab for 2 cases. The phenotypes were: wild phenotypes 23 cases (65.7%), resistant phenotypes 12 cases. Among resistant phenotypes, 4 were complex phenotype; 5 were ESBL phenotypes; 2 were hyper productive cephalosporinases phenotypes and 1 was a specific phenotype with impermeability to imipenem. Conclusion: The acquisition of resistance of Pseudomonas aeruginosa to beta lactam antibiotics in community infections among HIV-1 infected person incentives controls and promotes the rational use of antibiotics.

Share and Cite:

Wateba, M. , Ekoue-Kouvahey, K. , Balaka, A. , Tsatsu, K. and Tidjani, O. (2014) Resistance to Beta Lactam Antibiotics of Pseudomonas aeruginosa Isolated in Community Infections within HIV Infected Persons in Lomé-Togo. World Journal of AIDS, 4, 81-84. doi: 10.4236/wja.2014.41010.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Liu, P.V. and Mercer, C.B. (1963) Growth, and Virulence of Toxigenicity Pseudomonas Aeruginosa. The Journal of Hygiene, 61, 485-491.
[2] Feldman, M., Bryan, R., Rajan, S., Scheffler, L., Brunnert, S., Tang, H. and Prince, A. (1998) Role of Flagella in Pathogenesis of Pseudomonas aeruginosa Pulmonary Infection. Infection and Immunity, 66, 43-51.
[3] Bignandi, A. (2005) Vente illicite du médicament. Thèse de Pharmacie, Lomé, 34-39.
[4] MS/DGS/DES (2006) Répertoire des établissements privés de santé au Togo. 23-25.
[5] Jeannat, K. and Plesiat, P. (2005) Therapeutic Implication of Antibiotic Resistance in Pseudomonas. Lettre de l’infectiologue, 7.
[6] Navon-Venezia, S., Ben Ami, R. and Carmeli, Y. (2005) Update on Pseudomonas aeruginosa and Acinetobacter baumanii Infections in the Healthcare Setting. Current Opinion in Infectious Diseases, 18, 306-313.
[7] Faure, K., Kipnis, E. and Gueri, B. (2008) Prise en charge des pneumonies à Pseudomonas aeruginosa. Rev Tun Infectiol., 2, 1-8.
[8] Ait El Kadi, M., Aghrouch, M., Seffar, M., Elharti, J., Bouklouze, A., Cherrah, Y., et al. (2006) Prévalence des souches d'Acinetobacter baumannii et de Pseudomonas aeruginosa résistantes à l'imipénème par production de métallo-β-lactamases. Med Mal Infect., 36, 386-389.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.